Join Dr. Jairath on May 14, 8pm ET for webinar featuring a virtual review of the SECURE article (Strik et al, Lancet Gastroenterol Hepatol, Mar 2018).

Please join Dr. Vipul Jairath (CIBRN Chair) for WEBINAR 1 of 2018 to be held May 14 at 8pm EST, focused on the recent article in The Lancet Gastroenterology & Hepatology, by Strik et al:

Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial

Webinar access info was sent to you by email on May 4.

This year, acting on the suggestions from the 2017 yearend survey, we’re replacing ‘structured questions’ as catalysts for discussion in favour of 4 virtual reviews (VR) of articles of interest. It is hoped that by anchoring discussions in the context of important articles, that the exchange may be more organic in nature and ideally produce complementary veins of conversation.

Prior to the webinar, you are invited to read the article chosen as the subject of the first virtual review. See link above.

The webinar will be recorded and archived for future viewing by the CIBRN community.

If you have any comments or questions, please contact me at your convenience.

Paul Abbass
LEGITIMED INC.
Email: paul.abbass@legitimed.com

NEW for CIBRN: Virtual ReViews of key articles and perspectives from the literature. May 14 and June 20 at 8:00 pm ET.

Dear CIBRN Members,

Welcome to this year’s curriculum!

This year, rather than utilizing structured questions to advance discussions around the changing biosimilar landscape in Canada, we’re embracing a recommendation from our 2017 year-end survey, suggesting that we review key articles and perspectives from the literature. As such, we intend to host 4 Virtual ReViews (VRs), as we call them, in 2018.

Please mark your calendars for the first 2 VRs:

Mon, May 14, 8:00-9:00 pm EST, led by Dr. Vipul Jairath

Wed, June 20, 8:00 – 9:00 pm, led by Dr. Philip Baer

Webinar connection details will be sent to you by email. If you have any questions about the webinar or how to connect, please contact paul.abbass@legitimed.com.

VRs 3 & 4 will be scheduled for the Fall. Standby. In the meantime, we welcome your active participation in the Spring VRs.

Bye for now.

Paul Abbass
CIBRN Project Manager
(514) 358-2583

Segment 5 of Scientific reView on CIBRN TV: Click to view Drs. Khanna, Jairath and Baer on 1) Impact of the Article, 2) Role of the Clinician and 3) Role of the Payor

This week on Scientific reView, we highlight the final three video segments exploring 1) Impact of the Article, 2) Role of the Clinician and 3) Role of the Payor.

Click here to access the entire Scientific ReView: http://bit.ly/2oulNmw

As a reminder, the subject of the reView is the following article: Khanna R. Is a Biosimilar Interchangeable With an Originator? Gastroenterology 2017; 153:1160-1164 [download full text of article]

CIBRN members interviewed: Drs. Reena Khanna (London, Canada), Vipul Jairath (London, Canada) and Philip Baer (Scarborough, Canada).

Segment 4 of Scientific reView on CIBRN TV: Click to view Drs. Khanna, Jairath and Baer on clinical implications and NOR-SWITCH -interchangeability

This week on Scientific reView, we highlight the two video segments exploring (1) Clinical Implications and 2) NOR-SWITCH – Interchangeability.
Click here to access to the entire Scientific ReView: http://bit.ly/2oulNmw
As a reminder, the subject of the reView is the following article: Khanna RIs a Biosimilar Interchangeable With an Originator? Gastroenterology 2017; 153:1160-1164 [download full text of article]
CIBRN members interviewed: Drs. Reena Khanna (London, Canada), Vipul Jairath (London, Canada) and Philip Baer (Scarborough, Canada).

Segment 3 of Scientific reView on CIBRN TV: “Is a Biosimilar Interchangeable with an Originator?” Click to view Drs. Khanna, Jairath and Baer on Immunogenicity and Inferiority Margin

Welcome to CIBRN TV’s Scientific reView, video interviews with authors of key articles relevant to the CIBRN community. To view click here: http://bit.ly/2oulNmw
In this inaugural episode, we interview CIBRN members Drs. Reena Khanna (London, Canada), Vipul Jairath (London, Canada) and Philip Baer (Scarborough, Canada) on the article: Khanna RIs a Biosimilar Interchangeable With an Originator? Gastroenterology 2017; 153:1160-1164 [download full text of article]
This week, we highlight two CIBRN TV video segments exploring (1) Immunogenicity and (2) Inferiority Margin.
To view click here: http://bit.ly/2oulNmw

CIBRN TV Scientific reView: Is a Biosimilar Interchangeable with an Originator? Click to view Drs. Khanna, Jairath and Baer on NOR-SWITCH strengths and weaknesses

To view click here:  http://bit.ly/2oulNmw

Welcome to CIBRN TV’s Scientific reView, video interviews with authors of key articles relevant to the CIBRN community.

The article discussed: Khanna RIs a Biosimilar Interchangeable With an Originator? Gastroenterology 2017; 153:1160-1164 [download full text of article]

Those interviewed: Drs. Reena Khanna (London, Canada), Vipul Jairath (London, Canada) and Philip Baer (Scarborough, Canada).

This week, we highlight two video segments exploring (1) NOR-SWITCH – What is it? and 2) NOR-SWITCH – Strengths/Weaknesses.

To view click here:  http://bit.ly/2oulNmw

CIBRN TV Scientific reView: Is a Biosimilar Interchangeable with an Originator? Part 1: Impetus of the article & discussion of biosimilar versus generic.

It is with great pleasure that we introduce the inaugural segment of CIBRN TV’s Scientific reView, video interviews with authors of key articles relevant to the CIBRN community.

The article discussed: Khanna R. Is a Biosimilar Interchangeable With an Originator? Gastroenterology 2017; 153:1160-1164 [download full text]

Those interviewed: Drs. Reena Khanna (London, Canada), Vipul Jairath (London, Canada) and Philip Baer (Scarborough, Canada).

This week, we highlight the first two video segments exploring (1) the impetus of the article and (2) a discussion of Biosimilar versus Generic. By following the link below, you will have full access to the entire Scientific reView.

To view click here:  http://bit.ly/2oulNmw